Skip to main content

Table 1 Results of histomorphometrical analysis of effects of the treatments on LuCaP 23.1 and bone

From: Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

 

BV/TV (%)

TUV/TV (%)

TB.TH. (μM)

TB. N. (MM-1)

TB.SP. (μM)

OS.S./BS (%)

OS.TH. (μM)

OB.PM./BPM. (%)

N.OC./BS (%)

Control

23.09 ± 9.34

30.62 ± 5.75

94.89 ± 31.75

6.06 ± 1.41

76.87 ± 20.90

7.24 ± 1.82

4.57 ± 0.29

15.97 ± 5.08

1.91 ± 0.35

ZOL

36.51 ± 7.86

17.68 ± 6.79a

145.7 ± 31.64

5.08 ± 0.53

52.29 ± 13.51

3.96 ± 1.87

5.27 ± 0.45

8.46 ± 1.42a

0.83 ± 0.46a

DOC

29.46 ± 8.56

28.29 ± 11.18

81.53 ± 20.45

5.61 ± 0.90

100.6 ± 24.88

6.73 ± 1.84

5.21 ± 0.36

14.17 ± 4.36

1.19 ± 0.61

ZOL + DOC

40.38 ± 8.73a

11.13 ± 3.41a,b

118.5 ± 25.56

5.59 ± 0.51

61.48 ± 21.83

4.77 ± 1.01

4.98 ± 0.40

11.92 ± 5.90

0.77 ± 0.42a

  1. Tumored tibiae were harvested after seven weeks of treatment and embedded in methacrylate. Analysis was performed on Goldner-stained longitudinal sections of tibiae (n = 5 per group).
  2. Results are presented as a mean ± SD.
  3. a p < 0.5 vs. control group
  4. b p = 0.11 group 2 vs. group 4